MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-10-2025
RadNet Operating Income 2011-2026 | RDNT
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income RadNet
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 105 M | 98.7 M | 46.4 M | 82.6 M | 35.7 M | 69.9 M | 30.9 M | 50 M | 38.5 M | 39.1 M | 10.7 M | 11.6 M | 12.6 M | 8.39 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 105 M | 8.39 M | 45.7 M |
Quarterly Operating Income RadNet
| 2025-Q3 | 2025-Q2 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 27.4 M | 30.9 M | - | 33.9 M | 34.8 M | - | 43.3 M | 24.4 M | 6.67 M | - | 6.92 M | 19.6 M | -1.72 M | - | 32.6 M | 27.7 M | 17.7 M | - | 23.4 M | 179 K | -8.78 M | - | 16.8 M | 22 M | 7.27 M | - | 16.4 M | 15.9 M | -888 K | - | 10.8 M | 14.2 M | 6.75 M | - | 12.5 M | 8.08 M | 2.98 M | - | 17.2 M | 13.4 M | -1.95 M | - | 15.2 M | 15.6 M | 7.55 M | - | 8.59 M | 13 M | 8.32 M | - | 13.8 M | 13.5 M | 11.3 M | - | 11 M | 15.1 M | 8.9 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 43.3 M | -8.78 M | 14.5 M |
Operating Income of other stocks in the Diagnostics research industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Akumin
AKU
|
-28.1 M | - | -17.87 % | $ 25.9 M |  Canada |
|
Centogene N.V.
CNTG
|
-46 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Accelerate Diagnostics
AXDX
|
-14 M | - | -61.36 % | $ 2.46 M |  USA |
 |
Brainsway Ltd.
BWAY
|
-5 M | $ 19.02 | 0.21 % | $ 99.4 M |  Israel |
 |
Biocept
BIOC
|
-32 M | - | -13.05 % | $ 7.29 M | USA |
 |
Burning Rock Biotech Limited
BNR
|
-797 M | $ 20.15 | -2.3 % | $ 217 M |  China |
 |
Chembio Diagnostics
CEMI
|
-23.6 M | - | 0.22 % | $ 16.8 M | USA |
 |
Co-Diagnostics
CODX
|
-42.7 M | $ 0.17 | -6.7 % | $ 4.99 M | USA |
 |
Castle Biosciences
CSTL
|
8.67 M | $ 38.9 | -1.04 % | $ 1.08 B | USA |
 |
BioNano Genomics
BNGO
|
-104 M | $ 1.53 | 2.0 % | $ 1.94 M | USA |
 |
Danaher Corporation
DHR
|
4.86 B | $ 228.92 | -0.76 % | $ 167 B | USA |
 |
DexCom
DXCM
|
598 M | $ 66.37 | -1.03 % | $ 25.6 B | USA |
 |
Enzo Biochem
ENZ
|
-12.4 M | - | -8.98 % | $ 14.8 K | USA |
 |
DermTech
DMTK
|
-104 M | - | -11.32 % | $ 2.94 M | USA |
 |
DarioHealth Corp.
DRIO
|
-56.2 M | $ 11.38 | 6.36 % | $ 323 M | Israel |
 |
Exact Sciences Corporation
EXAS
|
-876 M | $ 101.56 | -0.33 % | $ 18.8 B | USA |
 |
Fulgent Genetics
FLGT
|
-73.9 M | $ 26.27 | -0.83 % | $ 794 M | USA |
 |
Global Cord Blood Corporation
CO
|
609 M | - | - | $ 399 M | China |
 |
Genetron Holdings Limited
GTH
|
-518 M | - | 0.12 % | $ 80.1 M | China |
 |
Heska Corporation
HSKA
|
-20.3 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
-20.8 M | - | -20.0 % | $ 1.06 M | USA |
 |
CareDx, Inc
CDNA
|
-203 M | $ 18.84 | -1.21 % | $ 1.01 B | USA |
 |
Celcuity
CELC
|
-113 M | $ 99.74 | -0.18 % | $ 3.93 B | USA |
 |
IQVIA Holdings
IQV
|
2.2 B | $ 225.41 | -1.0 % | $ 40.9 B | USA |
 |
Anixa Biosciences
ANIX
|
-13.8 M | $ 3.12 | - | $ 99.5 K | USA |
 |
Guardant Health
GH
|
-444 M | $ 102.14 | 1.53 % | $ 12.5 B | USA |
 |
Aspira Women's Health
AWH
|
-32.8 M | - | -6.19 % | $ 10.5 M | USA |
 |
Motus GI Holdings
MOTS
|
-11.9 M | - | -34.28 % | $ 263 K | Israel |
 |
Myriad Genetics
MYGN
|
-124 M | $ 6.15 | -0.32 % | $ 557 M | USA |
 |
Illumina
ILMN
|
-833 M | $ 131.16 | -1.2 % | $ 20.9 B | USA |
 |
Charles River Laboratories International
CRL
|
227 M | $ 199.48 | -1.24 % | $ 10.2 B | USA |
 |
ENDRA Life Sciences
NDRA
|
-10.8 M | $ 4.53 | -4.83 % | $ 2.43 M | USA |
 |
NeoGenomics
NEO
|
-92.1 M | $ 11.76 | -3.84 % | $ 1.49 B | USA |
 |
National Research Corporation
NRC
|
40 M | $ 18.77 | 0.64 % | $ 461 M | USA |
 |
Quest Diagnostics Incorporated
DGX
|
1.35 B | $ 173.53 | -1.12 % | $ 19.3 B | USA |
|
Biodesix
BDSX
|
-34.5 M | $ 6.8 | 1.19 % | $ 882 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
1.09 B | $ 250.88 | -0.87 % | $ 21 B | USA |
 |
ICON Public Limited Company
ICLR
|
1.1 B | $ 182.22 | -0.43 % | $ 15 B |  Irlanda |
 |
IDEXX Laboratories
IDXX
|
1.13 B | $ 676.53 | -0.85 % | $ 55.8 B | USA |
 |
Lantheus Holdings
LNTH
|
457 M | $ 66.55 | -0.91 % | $ 4.61 B | USA |
 |
Agilent Technologies
A
|
1.35 B | $ 136.07 | -1.13 % | $ 41.4 B | USA |
 |
Organovo Holdings
ONVO
|
-12.6 M | - | -2.3 % | $ 19.4 M | USA |
 |
Biomerica
BMRA
|
-5.14 M | $ 2.52 | 2.86 % | $ 5.79 M | USA |
 |
OpGen
OPGN
|
325 K | - | -16.95 % | $ 1.54 M | USA |
 |
OPKO Health
OPK
|
-152 M | $ 1.26 | -3.08 % | $ 874 M | USA |